Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10596241 | 0.85 | CES2 (0.45) | CES2CES1 | |
| SCHEMBL505097 | 0.82 | HCAR1 (0.53) | CES2CES1 | |
| SCHEMBL1764880 | 0.81 | VNN1 (0.46) | — | |
| SCHEMBL5222697 | 0.81 | CES2 (0.45) | CES2CES1 | |
| Hydrochloric Acid SCHEMBL6524503 | 0.81 | HCAR1 (0.52) | CES2CES1 | |
| SCHEMBL16960958 | 0.81 | PARP1 (0.46) | PARP1CES2CES1 | |
| SCHEMBL22557052 | 0.80 | VNN1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL22557478 | 0.79 | VNN1 (0.42) | — | |
| SCHEMBL7077548 | 0.79 | PARP1 (0.60) | PARP1CES2CES1 | |
| SCHEMBL259315 | 0.79 | CES2 (0.62) | PARP1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-01 | — | — | US | claimed |
| EP-2909190-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | claimed |
| WO-2014060386-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | claimed |
| EP-2722329-A1 | Indol-amide compounds as beta-amyloid inhbitors | F. Hoffmann-La Roche AG (CH) | 2014-04-23 | — | — | EP | claimed |
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | claimed |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | claimed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| EP-1917246-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | claimed |
| WO-2007020046-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | claimed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | claimed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | claimed |
| US-20240287104-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | RIGSHOSPITALET [DK]/[DK] (DK) | 2024-08-29 | — | — | US | disclosed |
| EP-4149931-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | Rigshospitalet (DK) | 2023-03-22 | — | — | EP | disclosed |
| WO-2021228992-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | RIGSHOSPITALET (DK) | 2021-11-18 | — | — | WO | disclosed |
| WO-2007035161-A1 | NEW PROCESS FOR CONVERTING AROMATIC HALO-SUBSTITUTED DINITRILES INTO HALO-SUBSTITUTED CYANOCARBOXYLIC ACIDS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007020046-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | PARP1 4842/4885CES2 725/4885CES1 792/4885 |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | CACNA1A, BMP4, TPX2 | PARP1 2516/4885CES2 3389/4885CES1 2174/4885 |
| US-20240287104-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | HUNK, NUCB2, TK1 | PARP1 980/4885CES2 2513/4885CES1 4300/4885 |
| US-20150274661-A1 | INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS | APP, BACE1, IAPP | PARP1 2825/4885CES2 847/4885CES1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.